These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35998390)

  • 1. Protective immunity triggered by ectonucleoside triphosphate diphosphohydrolase-based biopharmaceuticals attenuates cardiac parasitism and prevents mortality in Trypanosoma cruzi infection.
    Paula AT; Ribeiro KVG; Cardoso KF; Bastos DSS; Santos EC; Novaes RD; Cardoso SA; Oliveira LL
    Bioorg Med Chem; 2022 Oct; 72():116966. PubMed ID: 35998390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.
    de Alencar BC; Persechini PM; Haolla FA; de Oliveira G; Silverio JC; Lannes-Vieira J; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM
    Infect Immun; 2009 Oct; 77(10):4383-95. PubMed ID: 19651871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Ecto-nucleoside triphosphate diphosphohydrolase activity on Trypanosoma cruzi infectivity and virulence.
    Santos RF; Pôssa MA; Bastos MS; Guedes PM; Almeida MR; Demarco R; Verjovski-Almeida S; Bahia MT; Fietto JL
    PLoS Negl Trop Dis; 2009; 3(3):e387. PubMed ID: 19255624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.
    Gupta S; Garg NJ
    PLoS Pathog; 2015 May; 11(5):e1004828. PubMed ID: 25951312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
    Gupta S; Garg NJ
    PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
    Front Immunol; 2019; 10():1456. PubMed ID: 31293599
    [No Abstract]   [Full Text] [Related]  

  • 7. Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.
    Rigato PO; de Alencar BC; de Vasconcelos JR; Dominguez MR; Araújo AF; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM
    Infect Immun; 2011 May; 79(5):2120-30. PubMed ID: 21357719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
    Gupta S; Garg NJ
    Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.
    Hoft DF; Schnapp AR; Eickhoff CS; Roodman ST
    Infect Immun; 2000 Jan; 68(1):197-204. PubMed ID: 10603388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA-priming protein-boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain.
    Vasconcelos JR; Boscardin SB; Hiyane MI; Kinoshita SS; Fujimura AE; Rodrigues MM
    Immunol Cell Biol; 2003 Apr; 81(2):121-9. PubMed ID: 12631235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection.
    Boscardin SB; Kinoshita SS; Fujimura AE; Rodrigues MM
    Infect Immun; 2003 May; 71(5):2744-57. PubMed ID: 12704149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
    Chowdhury IH; Lokugamage N; Garg NJ
    Front Immunol; 2020; 11():595039. PubMed ID: 33414785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
    Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
    Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against Chagas disease.
    Gupta S; Silva TS; Osizugbo JE; Tucker L; Spratt HM; Garg NJ
    Infect Immun; 2014 Apr; 82(4):1382-9. PubMed ID: 24421046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs.
    Aparicio-Burgos JE; Ochoa-García L; Zepeda-Escobar JA; Gupta S; Dhiman M; Martínez JS; de Oca-Jiménez RM; Val Arreola M; Barbabosa-Pliego A; Vázquez-Chagoyán JC; Garg NJ
    PLoS Negl Trop Dis; 2011; 5(5):e1050. PubMed ID: 21625470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.
    Fujimura AE; Kinoshita SS; Pereira-Chioccola VL; Rodrigues MM
    Infect Immun; 2001 Sep; 69(9):5477-86. PubMed ID: 11500420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.
    Pereira IR; Vilar-Pereira G; Marques V; da Silva AA; Caetano B; Moreira OC; Machado AV; Bruna-Romero O; Rodrigues MM; Gazzinelli RT; Lannes-Vieira J
    PLoS Pathog; 2015 Jan; 11(1):e1004594. PubMed ID: 25617628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-10 limits parasite burden and protects against fatal myocarditis in a mouse model of Trypanosoma cruzi infection.
    Roffê E; Rothfuchs AG; Santiago HC; Marino AP; Ribeiro-Gomes FL; Eckhaus M; Antonelli LR; Murphy PM
    J Immunol; 2012 Jan; 188(2):649-60. PubMed ID: 22156594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trypanosoma cruzi: protective response of vaccinated mice is mediated by CD8+ cells, prevents signs of polyclonal T lymphocyte activation, and allows restoration of a resting immune state after challenge.
    Paiva CN; Castelo-Branco MT; Lannes-Vieira J; Gattass CR
    Exp Parasitol; 1999 Jan; 91(1):7-19. PubMed ID: 9920038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-10 participates in the expansion and functional activation of CD8
    Pino-Martínez AM; Miranda CG; Batalla EI; González-Cappa SM; Alba Soto CD
    J Leukoc Biol; 2019 Jan; 105(1):163-175. PubMed ID: 30371945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.